Durvalumab (D) compared to maintenance chemotherapy (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the randomized SAFIR02 LUNG-IMMUNO tria

  • Etude concernée: IFCT-1301
  • Auteurs / Authors: F. Barlesi, M. Karimi, P. Tomasini, C. Daniel, J. Raimbourg, A-E. Quoix, A-C. Madroszyk Flandin, J. Mazieres, O. Molinier, C. Audigier-Valette, D. Moro-Sibilot, H. Morel, P-J. Souquet, I. Bieche, A. Tran-Dien, A. Jacquet, J. Adam, J-C. Soria, B. Besse
  • Journal / Conference: ESMO
  • Année / Year: 2020
  • PMID: Poster
  • Lien vers la publication: https://www.annalsofoncology.org/article/S0923-7534(20)41583-2/fulltext